MY ACCOUNT | NEWSLETTER |

Centerline canine cementless total hip arthroplasty as an alternative implant system


C-THA can restore function in dogs with coxofemoral pathology.

Objective: To evaluate the clinical outcomes associated with the Biomedtrix Centerline canine cementless total hip arthroplasty implant (C-THA).

Animals: 17 dogs (20 hips) surgically implanted with C-THA to treat coxofemoral pathology.

Clinical presentation and procedures: Dogs with C-THA (2015 through 2020) with follow-up of ≥ 6 months were evaluated. Data included signalment, complications, management of complications, radiographs (bone implant interface), and clinical outcomes. Outcomes were assessed radiographically and subjectively via surgeon orthopedic examinations.

Results: 15 of 20 (75%) with long term radiographic follow-up had an excellent outcome. 5 hips (25%) had postoperative complications: femoral neck fracture (n = 1; 5%), aseptic loosening (2; 10%), and septic loosening (2; 10%).

Clinical relevance: C-THA can restore function in dogs with coxofemoral pathology. This novel procedure showed outcomes comparable to initial reports of other traditional THA implants (cemented, cementless, and hybrid) but complications occurred at a higher rate than recent outcomes of other long-standing THA procedures. Increased case numbers and surgeon experience with this novel implant system may eventually yield results comparable to other accepted THA systems.


Authors:  Gregory Zuendt, Daniel Stobie, Kei Hayashi
Source: https://avmajournals.avma.org/view/journals/javma/261/10/javma.23.02.0082.xml

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Feline injection site sarcomas

Like0
Dislike0

C-reactive protein concentrations in canine acute pancreatitis

Like0
Dislike0

A retrospective clinical investigation of the safety and adverse effects of pantoprazole in hospitalized ruminants

Like0
Dislike0

Dr. Marjorie Bercier Publishes Study on Novel Diagnostic Approach for Prevalent Elephant Virus

Like0
Dislike0

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top